Isolated +15 in bone marrow: Disease-associated or a benign finding?

Rashmi Shivani Goswami, Cynthia S. Liang, Carlos E. Bueso-Ramos, Shimin Hu, Maitrayee Goswami, C. Cameron Yin, Gary Lu, L. Jeffrey Medeiros, Guilin Tang

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

It has been controversial if trisomy 15 (+15) as an isolated clonal cytogenetic abnormality in bone marrow (BM) is disease-associated or a benign finding. To answer this question, we retrospectively reviewed our cytogenetic archives and identified 31 patients with isolated +15. Four patients presented with acute myeloid leukemia (AML), +15 was the major clone (56-95% of interphases) in BM and the clonal size of +15 was correlated with blast burden and disease status. For the remaining 27 patients, +15 was a minor clone (3-24% of interphases) in BM. Eighteen patients had a history of cytotoxic therapies and developed +15 after a median latency interval of 34 months. Six patients had BM involvement by lymphoma or myeloma, and +15 was exclusively detected in myeloid and erythroid cells, not in lymphoma or myeloma cells. With a median follow-up of 28 months, none of these 27 patients had clinical or morphological evidence of myelodysplastic syndromes. We conclude that +15 can be associated with AML, but more often isolated +15 presents as a minor clone in BM, and may not be disease associated. Clinical follow-up rather than an immediate therapeutic intervention seems most appropriate for non-leukemic patients with isolated +15.

Original languageEnglish (US)
Pages (from-to)72-76
Number of pages5
JournalLeukemia Research
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2015

Keywords

  • AML
  • Clinical significance
  • Post cytotoxic therapy
  • Trisomy 15

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Isolated +15 in bone marrow: Disease-associated or a benign finding?'. Together they form a unique fingerprint.

Cite this